Viridian Therapeutics Q4 2023 GAAP EPS $(1.35) Misses $(0.97) Estimate, Sales $72.00K Miss $159.60K Estimate
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics reported Q4 2023 GAAP EPS of $(1.35), missing the $(0.97) estimate, with sales of $72.00K also missing the $159.60K estimate. This represents a 31.43% decrease in sales compared to the same period last year.
February 27, 2024 | 10:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viridian Therapeutics missed Q4 2023 earnings and sales estimates, with a significant decrease in sales compared to last year.
Missing both earnings and sales estimates significantly, especially with a notable year-over-year decrease in sales, is likely to negatively impact investor sentiment and the stock price of Viridian Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100